Overview

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Single-blind, single-centre, fixed-order study to evaluate the PD effects of a single oral dose and multiple oral doses of ESL (BIA 2-093) in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Eslicarbazepine acetate